2015
Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331
Mitchell H, Lu X, Myers RM, Sung L, Balsamo LM, Carroll WL, Raetz E, Loh ML, Mattano LA, Winick NJ, Devidas M, Hunger SP, Maloney K, Kadan-Lottick N. Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331. International Journal Of Cancer 2015, 138: 332-339. PMID: 26235006, PMCID: PMC5138856, DOI: 10.1002/ijc.29708.Peer-Reviewed Original ResearchConceptsStandard-risk acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaLife Inventory 4.0 Generic Core ScalesChildren's Oncology Group studyHRQoL 1 monthMean PedsQL scoresYears of therapyHealth-related qualityEnd of inductionHigh cure ratesGeneric Core ScalesSocial functioningRepeated-measures analysisTherapy completionTherapeutic trialsCure ratePediatric QualityPedsQL scoresConsiderable impairmentLongitudinal assessmentDiagnosisTherapyMonthsGroup study
2014
Family life events in the first year of acute lymphoblastic leukemia therapy: A children's oncology group report
Lau S, Lu X, Balsamo L, Devidas M, Winick N, Hunger SP, Carroll W, Stork L, Maloney K, Kadan‐Lottick N. Family life events in the first year of acute lymphoblastic leukemia therapy: A children's oncology group report. Pediatric Blood & Cancer 2014, 61: 2277-2284. PMID: 25175168, PMCID: PMC4282930, DOI: 10.1002/pbc.25195.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaChildren's Oncology Group reportChildhood acute lymphoblastic leukemiaAcute lymphoblastic leukemia therapyMonths of therapyProspective cohort studyAppropriate anticipatory guidanceHigh cure ratesLong-term outcomesMore childrenHealth care providersLess maternal educationFirst yearCohort studyPatient factorsCure rateLymphoblastic leukemiaCOG protocolsCare providersAnticipatory guidanceEligibility criteriaHigh incidenceLeukemia therapyMaternal educationAverage risk